AU2006339445A1 - Methods for cancer therapy and stem cell modulation - Google Patents

Methods for cancer therapy and stem cell modulation Download PDF

Info

Publication number
AU2006339445A1
AU2006339445A1 AU2006339445A AU2006339445A AU2006339445A1 AU 2006339445 A1 AU2006339445 A1 AU 2006339445A1 AU 2006339445 A AU2006339445 A AU 2006339445A AU 2006339445 A AU2006339445 A AU 2006339445A AU 2006339445 A1 AU2006339445 A1 AU 2006339445A1
Authority
AU
Australia
Prior art keywords
cell
group
cells
tumour
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006339445A
Other languages
English (en)
Inventor
Jing Tan
Xiao Jing Yang
Qiang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of AU2006339445A1 publication Critical patent/AU2006339445A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006339445A 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation Abandoned AU2006339445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77853206P 2006-03-02 2006-03-02
US60/778,532 2006-03-02
PCT/SG2006/000350 WO2007100304A1 (en) 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation

Publications (1)

Publication Number Publication Date
AU2006339445A1 true AU2006339445A1 (en) 2007-09-07

Family

ID=38459334

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006339445A Abandoned AU2006339445A1 (en) 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation

Country Status (7)

Country Link
US (2) US8058258B2 (https=)
EP (2) EP1993553B1 (https=)
JP (3) JP5468782B2 (https=)
AU (1) AU2006339445A1 (https=)
SG (1) SG170041A1 (https=)
TW (1) TW200812590A (https=)
WO (1) WO2007100304A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
EP2334179A4 (en) * 2008-09-08 2012-09-26 Merck Sharp & Dohme AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
EP2331543A4 (en) * 2008-09-26 2013-06-19 Agency Science Tech & Res 3-deazaneplanocin DERIVATIVES
US8895526B2 (en) * 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
EP2646455A4 (en) * 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
WO2012159085A2 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
CA2887461A1 (en) * 2012-07-09 2014-01-16 Metheor Therapeutics Corporation Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
JP2016517426A (ja) 2013-03-15 2016-06-16 エピザイム，インコーポレイティド 置換プリン化合物の合成方法
WO2016022563A1 (en) 2014-08-04 2016-02-11 Auburn University Enantiomers of the 1',6'-isomer of neplanocin a
WO2016149299A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
WO2023249714A1 (en) * 2022-06-24 2023-12-28 Memorial Sloan-Kettering Cancer Center Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510260A (en) 1893-12-05 Electric-arc-lighting system
US4968690A (en) 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
EP1536688B1 (en) 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
WO2004046312A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
US20050266093A1 (en) 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
MX2007000770A (es) 2004-07-20 2007-03-26 Schering Corp Induccion de apoptosis en celulas tumorales que expresan el receptor tipo toll.

Also Published As

Publication number Publication date
JP5902138B2 (ja) 2016-04-13
EP2522352A1 (en) 2012-11-14
US20100075915A1 (en) 2010-03-25
JP2013121974A (ja) 2013-06-20
JP2009528345A (ja) 2009-08-06
TW200812590A (en) 2008-03-16
EP2522352B1 (en) 2017-01-11
US8211869B2 (en) 2012-07-03
EP1993553A4 (en) 2010-07-28
US20120077841A1 (en) 2012-03-29
JP2014028853A (ja) 2014-02-13
US8058258B2 (en) 2011-11-15
EP1993553A1 (en) 2008-11-26
WO2007100304A1 (en) 2007-09-07
SG170041A1 (en) 2011-04-29
JP5468782B2 (ja) 2014-04-09
EP1993553B1 (en) 2013-05-08

Similar Documents

Publication Publication Date Title
US8211869B2 (en) Methods for cancer therapy and stem cell modulation
US12516318B2 (en) Targeting glioblastoma stem cells through the TLX-TET3 axis
WO2014046617A1 (en) Compositions and methods for treating cancer
Grossauer et al. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model
CA2782527C (en) Uses of hypoxia-inducible factor inhibitors
Giladi et al. RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop
Mao et al. Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway
WO2017155935A1 (en) Pharmaceutical agents targeting cancer stem cells
WO2025087879A2 (en) Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
CN114574580B (zh) 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
Anna Ciechomska et al. Glioblastoma stem-like cells–isolation, biology and mechanisms of chemotherapy resistance
JP2017518353A (ja) 薬剤耐性癌の治療又は腫瘍再燃の予防のための、ｄｎａメチル化阻害剤とビタミンｄ受容体アゴニストとの組み合わせを含む組成物
EP4299742A1 (en) Combination therapy for melanoma
Wang et al. Survivin Inhibition Induces Cell Cycle Arrest and Disrupts Multipotency in Haemangioma Stem Cells.
Hosseini DISSECTING THE ROLE OF LYSINE-SPECIFIC DEMETHYLASE1 (LSD1): IDENTIFICATION OF MARKERS/EFFECTORS OF SENSITIVITY TO LSD1 INHIBITORS IN CANCER.
KIM The Role of Polycomb Repressive Complex 2 and Effects of Lobarstin in Glioblastoma Multiforme
WO2024003350A1 (en) Combination therapy for melanoma
TWI585204B (zh) 用以治療癌症之短干擾核糖核酸分子
WO2026013071A1 (en) Setdb1 inhibitor for use in the treatment of uveal melanoma
Yan Role of Mir-29b in the Regulation of Progranulin and Dna Methyltransferases 3a and 3b Expression: Therapeutic Potential in Glioblastoma
WO2020153503A1 (ja) ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤
Yee Targeting the transcription factor c-Jun in cervical cancer cells
Sharma Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia
Breslin The primary cilium as a regulator of cellular senescence in human fibroblasts
Xiang-Zhong et al. Analyzing Gene Expression Profile in K562 Cells Exposed to Sodium Valproate Using Microarray Combined with the Connectivity Map Database

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application